Market Flux Event
Merck and Eisai Report Welireg Plus Lenvatinib Hits PFS Goal in Previously Treated Advanced Kidney Cancer
Read this in the Market Flux appMerck and Eisai announced that the combination of Welireg (belzutifan) and lenvatinib met its dual primary endpoint in patients with advanced clear cell renal cell carcinoma who had previously received a PD-1 or PD-L1 inhibitor, delivering a statistically significant and clinically meaningful improvement in progression-free survival. The combination was tested against cabozantinib, the current standard of care in that setting, and reduced the risk of disease progression or death by 30%, with a median PFS of 14.8 months compared to 10.7 months for cabozantinib.
© AI-generated summary is provided by Market Flux
Sources
- MarketsdayMerck’s Welireg Plus Lenvatinib Meets PFS Goal in Advanced Kidney Cancer – November 13, 2026 🔹 Merck $MRK announced that the combination of Welireg (belzutifan) and lenvatinib achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS). 🔹 The combination met the dual primary endpoint in patients with advanced clear cell renal cell carcinoma (ccRCC). 🔹 The trial involved patients previously treated with a PD-1 or PD-L1 inhibitor. \#Merck #MRK #Welireg #Lenvatinib #Oncology #CancerResearch #PharmaStocks
- OpenOutcrier$RZLT (+4.4% pre) Rezolute's Phase 3 tumor hyperinsulinism study hits primary endpoint
- Newsfile_CorpOS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company Full Story: #ostherapies $OSTX #Chemicals #Biotechnology #Investing
- Seeking AlphaRezolute releases interim phase 3 results of ersodetug in tumor hyperinsulinism
- Proactive_X$IMUX Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027 @ImmunicInc #IMUX